These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1341 related articles for article (PubMed ID: 1712633)
1. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion. Bizik J; Lizonová A; Stephens RW; Grófová M; Vaheri A Cell Regul; 1990 Nov; 1(12):895-905. PubMed ID: 1712633 [TBL] [Abstract][Full Text] [Related]
2. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891 [TBL] [Abstract][Full Text] [Related]
3. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Meissauer A; Kramer MD; Schirrmacher V; Brunner G Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956 [TBL] [Abstract][Full Text] [Related]
4. Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Stephens RW; Tapiovaara H; Reisberg T; Bizik J; Vaheri A Cell Regul; 1991 Dec; 2(12):1057-65. PubMed ID: 1724917 [TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. Saksela O; Hovi T; Vaheri A J Cell Physiol; 1985 Jan; 122(1):125-32. PubMed ID: 2578131 [TBL] [Abstract][Full Text] [Related]
6. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329 [TBL] [Abstract][Full Text] [Related]
7. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891 [TBL] [Abstract][Full Text] [Related]
8. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136 [TBL] [Abstract][Full Text] [Related]
9. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. Tsuboi R; Rifkin DB Int J Cancer; 1990 Jul; 46(1):56-60. PubMed ID: 2142142 [TBL] [Abstract][Full Text] [Related]
10. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. Andreasen PA; Christensen TH; Huang JY; Nielsen LS; Wilson EL; Danø K Mol Cell Endocrinol; 1986 May; 45(2-3):137-47. PubMed ID: 3011558 [TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix. Mimura K; Sueishi K; Yasunaga C; Tanaka K Invasion Metastasis; 1992; 12(1):24-34. PubMed ID: 1380952 [TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. Hajjar KA; Hamel NM J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465 [TBL] [Abstract][Full Text] [Related]
13. Binding of tissue-type plasminogen activator to human melanoma cells. Bizik J; Stephens RW; Grofova M; Vaheri A J Cell Biochem; 1993 Mar; 51(3):326-35. PubMed ID: 8501135 [TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator. Sitter T; Toet K; Quax P; Kooistra T Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells. Wojta J; Gallicchio M; Zoellner H; Filonzi EL; Hamilton JA; McGrath K Blood; 1993 Jun; 81(12):3285-92. PubMed ID: 8507866 [TBL] [Abstract][Full Text] [Related]
16. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Mars WM; Kim TH; Stolz DB; Liu ML; Michalopoulos GK Cancer Res; 1996 Jun; 56(12):2837-43. PubMed ID: 8665523 [TBL] [Abstract][Full Text] [Related]
17. Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor. Durko M; Brodt P Biochem Biophys Res Commun; 1998 Jun; 247(2):342-8. PubMed ID: 9642128 [TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680 [TBL] [Abstract][Full Text] [Related]
19. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Cohen RL; Xi XP; Crowley CW; Lucas BK; Levinson AD; Shuman MA Blood; 1991 Jul; 78(2):479-87. PubMed ID: 1648983 [TBL] [Abstract][Full Text] [Related]
20. Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro. Tapiovaara H; Stephens RW; Vaheri A Int J Cancer; 1993 Feb; 53(3):499-505. PubMed ID: 8428801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]